[1] Wang S, Song K, Guo X, et al. The association of metabolic syndrome with left ventricular mass and geometry in community-based hypertensive patients among Han Chinese[J]. J Res Med Sci, 2015, 20(10):963-968. [2] Jaleta G N, Gudina E K, Getinet W. Left ventricular hypertrophy among black hypertensive patients:focusing on the efficacy of angiotensin converting enzyme inhibitors[J]. BMC Res Notes, 2014, 7:45. [3] Yang Y, Xu J Z, Wang Y, et al. Brachial flow-mediated dilation predicts subclinical target organ damage progression in essential hypertensive patients:a 3-year follow-up study[J]. J Hypertens, 2014, 32(12):2393-2400. [4] 高血压联盟(中国),中华医学会心血管病学分会,中国医师协会高血压专业委员会,等.中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019,19(1):1-44. [5] Gkaliagkousi E, Gavriilaki E, Triantafyllou A, et al. Clinical significance of endothelial dysfunction in essential hypertension[J]. Curr Hypertens Rep, 2015, 17(11):85. [6] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. J Eur Heart J, 2018, 39(33):3021-3104. [7] Domsic R T, Dezfulian C, Shoushtari A, et al. Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients[J]. Clin Exp Rheumatol, 2014, 32(6 Suppl 86):S154-160. [8] Muller U, Matsuo Y, Lauber M, et al. Correlation between endothelial function measured by finger plethysmography in children and HDL-mediated eNOS activation-a preliminary study[J]. Metabolism, 2013, 62(5):634-637. [9] Mudau M, Genis A, Lochner A, et al. Endothelial dysfunction:the early predictor of atherosclerosis[J]. Cardiovasc J Afr, 2012, 23(4):222-231. [10] Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction predicts regression of hypertensive cardiac mass[J]. Int J Cardiol, 2013, 167(4):1188-1192. [11] Kao M P, Ang D S, Gandy S J, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease[J]. J Am Soc Nephrol, 2011, 22(7):1382-1389. [12] Meeme A, Buga G A, Mammen M, et al. Endothelial dysfunction and arterial stiffness in pre-eclampsia demonstrated by the EndoPAT method[J]. Cardiovasc J Afr, 2017, 28(1):23-29. [13] Cao C, Hu J X, Dong Y F, et al. Association of Endothelial and Mild Renal Dysfunction With the Severity of Left Ventricular Hypertrophy in Hypertensive Patients[J]. Am J Hypertens, 2016, 29(4):501-508. [14] Adiarto S, Heiden S, Vignon-Zellweger N, et al. ET-1 from endothelial cells is required for complete angiotensin Ⅱ-induced cardiac fibrosis and hypertrophy[J]. Life Sci, 2012, 91(13-14):651-657. [15] Rebic D, Rasic S, Rebic V. Influence of endothelin-1 and nitric oxide on left ventricular remodelling in patients on peritoneal dialysis[J]. Ren Fail, 2014, 36(2):232-236. [16] 周亚群, 丁存涛, 孙希鹏, 等. 原发性高血压病人超敏C反应蛋白与血压及血管内皮功能关系的研究[J]. 首都医科大学学报, 2017, 38(3):397-400. [17] Mordi I, Mordi N, Delles C, et al. Endothelial dysfunction in human essential hypertension[J]. J Hypertens, 2016, 34(8):1464-1472. [18] Moerland M, Kales A J, Schrier L, et al. Evaluation of the EndoPAT as a tool to assess endothelial function[J]. Int J Vasc Med, 2012, 2012:904141. [19] 谢蒂立, 程标,金静.厄贝沙坦治疗高血压合并冠心病患者疗效及对血管内皮功能和炎性因子的影响[J].解放军医药杂志,2018,30(2):78-81. [20] 吕曼. 小剂量氢氯噻嗪联合厄贝沙坦治疗原发性高血压的临床观察[J].首都医科大学学报,2018,39(1):148-152. |